citric acid, anhydrous has been researched along with Glucose Intolerance in 7 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) and its evolution to inflammatory steatohepatitis (NASH) are the most common causes of chronic liver damage and transplantation that are reaching epidemic proportions due to the upraising incidence of metabolic syndrome, obesity, and diabetes." | 1.56 | Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. ( Albanese, C; Avantaggiati, ML; Catalina-Rodriguez, O; Cheema, A; Foley, P; Gadre, S; Giaccone, G; Graham, GT; Kallakury, B; Kasprzyk-Pawelec, A; Mosaoa, R; Parasido, E; Tan, M; Yi, C, 2020) |
| "Metabolic syndrome (MetS), following intrauterine growth restriction (IUGR), is epigenetically heritable." | 1.42 | Heritable IUGR and adult metabolic syndrome are reversible and associated with alterations in the metabolome following dietary supplementation of 1-carbon intermediates. ( Aagaard, KM; Chu, DM; Cox, JE; Gonzalez-Rodriguez, PJ; Goodspeed, DM; Krannich, LA; Seferovic, MD, 2015) |
| "The pathogenesis of nephrolithiasis in Cushing's syndrome is still not completely clarified." | 1.32 | Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. ( Colao, A; Di Somma, C; Faggiano, A; Filippella, M; Lombardi, G; Melis, D; Petretta, M; Pivonello, R, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, M | 1 |
| Mosaoa, R | 1 |
| Graham, GT | 1 |
| Kasprzyk-Pawelec, A | 1 |
| Gadre, S | 1 |
| Parasido, E | 1 |
| Catalina-Rodriguez, O | 1 |
| Foley, P | 1 |
| Giaccone, G | 1 |
| Cheema, A | 1 |
| Kallakury, B | 1 |
| Albanese, C | 1 |
| Yi, C | 1 |
| Avantaggiati, ML | 1 |
| Nakamura, Y | 1 |
| Haraguchi, A | 1 |
| Shigeno, R | 1 |
| Ito, A | 1 |
| Horie, I | 1 |
| Kawakami, A | 1 |
| Abiru, N | 1 |
| Branco, JR | 1 |
| Esteves, AM | 1 |
| Leandro, JGB | 1 |
| Demaria, TM | 2 |
| Godoi, V | 1 |
| Marette, A | 1 |
| Valença, HDM | 1 |
| Lanzetti, M | 1 |
| Peyot, ML | 1 |
| Farfari, S | 1 |
| Prentki, M | 1 |
| Zancan, P | 2 |
| Sola-Penna, M | 2 |
| Bonetti, G | 1 |
| Giavarina, D | 1 |
| Carta, M | 1 |
| Seferovic, MD | 1 |
| Goodspeed, DM | 1 |
| Chu, DM | 1 |
| Krannich, LA | 1 |
| Gonzalez-Rodriguez, PJ | 1 |
| Cox, JE | 1 |
| Aagaard, KM | 1 |
| Leandro, JG | 1 |
| Espindola-Netto, JM | 1 |
| Vianna, MC | 1 |
| Gomez, LS | 1 |
| Marinho-Carvalho, MM | 1 |
| Paula Neto, HA | 1 |
| Faggiano, A | 1 |
| Pivonello, R | 1 |
| Melis, D | 1 |
| Filippella, M | 1 |
| Di Somma, C | 1 |
| Petretta, M | 1 |
| Lombardi, G | 1 |
| Colao, A | 1 |
1 trial available for citric acid, anhydrous and Glucose Intolerance
| Article | Year |
|---|---|
A single-arm, open-label, intervention study to investigate the improvement of glucose tolerance after administration of the 5-aminolevulinic acid (5-ALA) in the patients with mitochondrial diabetes mellitus.
Topics: Adenosine Triphosphate; Adult; Aminolevulinic Acid; Blood Glucose; Citric Acid; Deafness; Diabetes M | 2021 |
6 other studies available for citric acid, anhydrous and Glucose Intolerance
| Article | Year |
|---|---|
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH.
Topics: Acetyl Coenzyme A; Animals; Blood Glucose; Carrier Proteins; Cell Polarity; Citric Acid; Diet, High- | 2020 |
Dietary citrate acutely induces insulin resistance and markers of liver inflammation in mice.
Topics: Animals; Citric Acid; Diet; Glucose; Glucose Intolerance; Glucose Tolerance Test; Glycogen Synthase | 2021 |
Clinical impact of citrate-containing tubes on the detection of glucose abnormalities by the oral glucose tolerance test.
Topics: Adolescent; Adult; Anticoagulants; Blood Glucose; Carbohydrate Metabolism; Citric Acid; Diabetes, Ge | 2019 |
Heritable IUGR and adult metabolic syndrome are reversible and associated with alterations in the metabolome following dietary supplementation of 1-carbon intermediates.
Topics: Animal Nutritional Physiological Phenomena; Animals; Animals, Newborn; Body Weight; Citric Acid; Die | 2015 |
Exogenous citrate impairs glucose tolerance and promotes visceral adipose tissue inflammation in mice.
Topics: Animals; Citric Acid; Cytokines; Diet, Western; Dietary Sucrose; Food Additives; Glucose Intolerance | 2016 |
Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure.
Topics: Adult; Analysis of Variance; Body Mass Index; Calcium; Citric Acid; Cushing Syndrome; Cystine; Cysti | 2003 |